Q-omics provides the consensus-scored TBCA profile across patient tissues and cancer cell-line models. TBCA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TBCA is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TBCA RNA expression shows 18,993 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KIRC, and ACC as cancer lineages where TBCA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBCA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBCA survival associations across molecular data types. TBCA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBCA RNA expression–survival associations across cancer types. High TBCA expression shows unfavorable associations in HNSC, KICH, SCLC, UVM, KIRP and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TBCA RNA expression.
This table summarizes TBCA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TBCA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBCA shows higher tumor expression in KIRC, HNSC, LIHC, BRCA, CHOL and COAD. The KIRC box plot shows higher TBCA RNA expression in tumor versus normal tissue (log2 FC = +0.815, t-test p < 0.001).
This table shows molecular features associated with TBCA in patient tissues and cancer cell lines. In patient samples, TBCA shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TBCA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and OVARY.
